<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542696</url>
  </required_header>
  <id_info>
    <org_study_id>CTH-301</org_study_id>
    <secondary_id>2016-000637-43</secondary_id>
    <nct_id>NCT02542696</nct_id>
  </id_info>
  <brief_title>Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of &quot;OFF&quot; Episodes in Patients With Parkinson's Disease</brief_title>
  <official_title>An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (&quot;OFF&quot; Episodes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of&#xD;
      APL-130277 for the Acute Treatment of &quot;OFF&quot; Episodes in Patients With Parkinson's Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability data collected, based on incidence of adverse events in the LTS phase</measure>
    <time_frame>Throughout the entire study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Mean change from pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) score at 15, 30, 60, and 90 minutes after dosing at Week 24, Week 36, and Week 48 visits (LTS V4, V5, and V6) of the LTS Phase.</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Percentage of subjects with a subject-rated full &quot;ON&quot; response within 30 minutes at Week 24, Week 36, and Week 48 visits (LTS V4, V5, and V6) of the LTS Phase.</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. The percentage of instances where a full &quot;ON&quot; response was achieved within 30 minutes after self-administration of study medication at Week 24, Week 36, and Week 48 visits (LTS V4, V5, and V6) of the LTS Phase based on the home dosing diary entries.</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>APL-130277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-130277</intervention_name>
    <description>Used to treat up to 5 &quot;OFF&quot; episodes per day</description>
    <arm_group_label>APL-130277</arm_group_label>
    <other_name>Apomorphine Hydrochloride, Sublingual Thin Film</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        De Novo Subjects Inclusion Criteria&#xD;
&#xD;
          1. Male or female ≥ 18 years of age.&#xD;
&#xD;
          2. Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria (excluding&#xD;
             the &quot;more than one affected relative&quot; criterion)&#xD;
&#xD;
          3. Clinically meaningful response to L-Dopa as determined by the Investigator.&#xD;
&#xD;
          4. Receiving stable doses of L-Dopa/carbidopa (immediate or CR) administered at least 4&#xD;
             times per day OR Rytary™ administered at least 3 times per day, for at least 4 weeks&#xD;
             before the initial Screening Visit (SV1). Adjunctive PD medication regimens must be&#xD;
             maintained at a stable dose for at least 4 weeks prior to the initial Screening Visit&#xD;
             (SV1) with the exception that MAO-B inhibitors must be maintained at a stable level&#xD;
             for at least 8 weeks prior to the initial Screening Visit (SV1).&#xD;
&#xD;
          5. No planned medication change(s) or surgical intervention anticipated during the course&#xD;
             of study.&#xD;
&#xD;
          6. Subject must experience at least one well defined &quot;OFF&quot; episode per day with a total&#xD;
             daily &quot;OFF&quot; time duration of ≥ 2 hours during the waking day, based on patient&#xD;
             self-assessment.&#xD;
&#xD;
          7. Subject and/or caregiver must be trained in performing home dosing diary assessments&#xD;
             of the motor state and must be able to recognize &quot;ON&quot; and &quot;OFF&quot; states.&#xD;
&#xD;
          8. Stage III or less on the modified Hoehn and Yahr scale in the &quot;ON&quot; state.&#xD;
&#xD;
          9. MMSE score &gt; 25.&#xD;
&#xD;
         10. If female and of childbearing potential, must agree to be sexually abstinent or use&#xD;
             one of the following highly effective methods of birth control:&#xD;
&#xD;
               -  Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring,&#xD;
                  injectables, and implants);&#xD;
&#xD;
               -  Intrauterine contraceptive system;&#xD;
&#xD;
               -  Surgical sterilization or partner sterile (must have documented proof); AND&#xD;
&#xD;
             One of the following effective methods of birth control:&#xD;
&#xD;
               -  Male/female condom;&#xD;
&#xD;
               -  Cervical cap with spermicide;&#xD;
&#xD;
               -  Diaphragm with spermicide;&#xD;
&#xD;
               -  Contraceptive sponge.&#xD;
&#xD;
         11. Male subjects must be either surgically sterile, agree to be sexually inactive or use&#xD;
             a double-barrier method of birth control (eg, condom and diaphragm with spermicide,&#xD;
             condom with cervical cap and spermicide) from first study drug administration until 90&#xD;
             days after final drug administration.&#xD;
&#xD;
         12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study-related procedures.&#xD;
&#xD;
         13. Able to understand the consent form, and to provide written informed consent.&#xD;
&#xD;
        De Novo Subjects Exclusion Criteria -&#xD;
&#xD;
          1. Atypical or secondary parkinsonism.&#xD;
&#xD;
          2. Previous treatment with any of the following: a neurosurgical procedure for PD;&#xD;
             continuous s.c. apomorphine infusion; Duodopa/Duopa; or APL-130277.&#xD;
&#xD;
          3. Treatment with any form of s.c. apomorphine within 7 days prior to the second&#xD;
             Screening Visit (SV2). Patients that stopped s.c. apomorphine for any reason other&#xD;
             than systemic safety concerns or lack of efficacy may be considered.&#xD;
&#xD;
          4. Contraindications to APOKYN®, or hypersensitivity to apomorphine hydrochloride or any&#xD;
             of the ingredients of APOKYN® (notably sodium metabisulfite).&#xD;
&#xD;
          5. Female who is pregnant or lactating.&#xD;
&#xD;
          6. Participation in a clinical trial within 30 days prior to the initial Screening Visit&#xD;
             (SV1).&#xD;
&#xD;
          7. Receipt of any investigational (ie, unapproved) medication within 30 days prior to the&#xD;
             initial Screening Visit (SV1).&#xD;
&#xD;
          8. Currently taking selective 5HT3 antagonists (ie, ondansetron, granisetron, dolasetron,&#xD;
             palonosetron, alosetron), dopamine antagonists (excluding quetiapine or clozapine) or&#xD;
             dopamine depleting agents.&#xD;
&#xD;
          9. Drug or alcohol dependency in the past 12 months.&#xD;
&#xD;
         10. Subject has a history of malignancy within 5 years prior to the Screening visit,&#xD;
             except for adequately treated basal cell or squamous cell skin cancer or in situ&#xD;
             cervical cancer. Pituitary tumors of any duration are excluded.&#xD;
&#xD;
         11. Clinically significant medical, surgical, or laboratory abnormality in the opinion of&#xD;
             the Investigator.&#xD;
&#xD;
         12. Major psychiatric disorder including, but not limited to, dementia, bipolar disorder,&#xD;
             psychosis, or any disorder that, in the opinion of the Investigator, requires ongoing&#xD;
             treatment that would make study participation unsafe or make treatment compliance&#xD;
             difficult.&#xD;
&#xD;
         13. History of clinically significant hallucinations during the past 6 months.&#xD;
&#xD;
         14. History of clinically significant impulse control disorder(s).&#xD;
&#xD;
         15. Dementia that precludes providing informed consent or would interfere with&#xD;
             participation in the study.&#xD;
&#xD;
         16. Current suicidal ideation within one year prior to the second Screening Visit (SV2) as&#xD;
             evidenced by answering &quot;yes&quot; to Questions 4 or 5 on the suicidal ideation portion of&#xD;
             the C-SSRS or attempted suicide within the last 5 years.&#xD;
&#xD;
         17. Donation of blood or plasma in the 30 days prior to first dosing.&#xD;
&#xD;
         18. Presence of canker or mouth sores in the 30 days prior to the initial Screening Visit&#xD;
             (SV1), or other clinically significant oral pathology in the opinion of the&#xD;
             Investigator. The Investigator should follow-up with an appropriate specialist on any&#xD;
             finding, if indicated, before enrolling a patient into the study.&#xD;
&#xD;
        Rollover Subjects Inclusion Criteria&#xD;
&#xD;
          1. Completion of any of the following studies: CTH-201, CTH-203, CTH-300, or CTH 302;&#xD;
             and, in the opinion of the Investigator, would benefit from continued treatment with&#xD;
             APL 130277.&#xD;
&#xD;
          2. No major changes in concomitant PD medications since completion of any of the&#xD;
             following studies: CTH-201, CTH-203, CTH-300, or CTH 302. Any change in PD medications&#xD;
             since the previous study should be discussed with the Medical Monitor to determine&#xD;
             subject eligibility in the current study.&#xD;
&#xD;
          3. If female and of childbearing potential, must agree to be sexually abstinent or use&#xD;
             one of the following highly effective methods of birth control:&#xD;
&#xD;
               -  Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring,&#xD;
                  injectables, and implants);&#xD;
&#xD;
               -  Intrauterine contraceptive system;&#xD;
&#xD;
               -  Surgical sterilization or partner sterile (must have documented proof); AND&#xD;
&#xD;
             One of the following effective methods of birth control:&#xD;
&#xD;
               -  Male/female condom;&#xD;
&#xD;
               -  Cervical cap with spermicide;&#xD;
&#xD;
               -  Diaphragm with spermicide;&#xD;
&#xD;
               -  Contraceptive sponge.&#xD;
&#xD;
          4. Male subjects must be either surgically sterile, agree to be sexually inactive or use&#xD;
             a double-barrier method of birth control (eg, condom and diaphragm with spermicide,&#xD;
             condom with cervical cap and spermicide) from first study drug administration until 90&#xD;
             days after final drug administration.&#xD;
&#xD;
          5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study-related procedures.&#xD;
&#xD;
          6. Able to understand the consent form, and to provide written informed consent.&#xD;
&#xD;
        Rollover Subjects Exclusion Criteria&#xD;
&#xD;
          1. Female who is pregnant or lactating.&#xD;
&#xD;
          2. Presence of any major psychiatric disorder including, but not limited to, dementia,&#xD;
             bipolar disorder, psychosis (including clinically significant hallucinations during&#xD;
             the past 6 months) or any disorder that, in the opinion of the Investigator, requires&#xD;
             ongoing treatment that would make study participation unsafe or make treatment&#xD;
             compliance difficult.&#xD;
&#xD;
          3. Presence of any clinically significant medical (including but not limited to CNS,&#xD;
             cardiovascular, hepatic, pulmonary, metabolic, or renal events), surgical, or&#xD;
             laboratory abnormality that would make study participation unsafe or make treatment&#xD;
             compliance difficult. Clinical significance to be determined by the Investigator.&#xD;
&#xD;
          4. Receipt of any investigational (ie, unapproved) medication or participation in any&#xD;
             clinical trial of an investigational product since completing a previous study using&#xD;
             APL 130277.&#xD;
&#xD;
          5. Development of canker or mouth sores within 14 days of completing a previous study&#xD;
             using APL-130277. For other clinically significant oral pathology, the Investigator&#xD;
             should follow-up with an appropriate specialist on any finding, if indicated, before&#xD;
             enrolling such a subject into the study. Clinical significance to be determined by the&#xD;
             Investigator. The eligibility of subjects who have experienced AEs related to the oral&#xD;
             cavity during the previous study using APL-130277, should be reviewed with the medical&#xD;
             monitor and approval obtained.&#xD;
&#xD;
          6. Current suicidal ideation within one year of the screening visit, as evidenced by&#xD;
             answering &quot;yes&quot; to Question 4 or 5 on the suicidal ideation portion of the C SSRS at&#xD;
             Screening or attempted suicide within 5 years.&#xD;
&#xD;
        CTH-301 Completer Subjects Inclusion Criteria&#xD;
&#xD;
          1. Completion of the CTH-301 study under protocol version 3.00, and in the opinion of the&#xD;
             Investigator, would benefit from continued treatment with APL 130277.&#xD;
&#xD;
          2. If female and of childbearing potential, must agree to be sexually abstinent or use&#xD;
             one of the following highly effective methods of birth control:&#xD;
&#xD;
               -  Hormonal contraceptives (eg, combined oral contraceptives, patch, vaginal ring,&#xD;
                  injectables, and implants);&#xD;
&#xD;
               -  Intrauterine contraceptive system;&#xD;
&#xD;
               -  Surgical sterilization or partner sterile (must have documented proof); AND&#xD;
&#xD;
             One of the following effective methods of birth control:&#xD;
&#xD;
               -  Male/female condom;&#xD;
&#xD;
               -  Cervical cap with spermicide;&#xD;
&#xD;
               -  Diaphragm with spermicide;&#xD;
&#xD;
               -  Contraceptive sponge.&#xD;
&#xD;
          3. Male subjects must be either surgically sterile, agree to be sexually inactive or use&#xD;
             a double-barrier method of birth control (eg, condom and diaphragm with spermicide,&#xD;
             condom with cervical cap and spermicide) from first study drug administration until 90&#xD;
             days after final drug administration.&#xD;
&#xD;
          4. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study-related procedures.&#xD;
&#xD;
          5. Able to understand the consent form, and to provide written informed consent.&#xD;
&#xD;
        CTH-301 Completer Subjects Exclusion Criteria&#xD;
&#xD;
          1. Female who is pregnant or lactating.&#xD;
&#xD;
          2. Presence of any major psychiatric disorder including, but not limited to, dementia,&#xD;
             bipolar disorder, psychosis (including clinically significant hallucinations during&#xD;
             the past 6 months) or any disorder that, in the opinion of the Investigator, requires&#xD;
             ongoing treatment that would make study participation in unsafe or make treatment&#xD;
             compliance difficult.&#xD;
&#xD;
          3. Presence of any clinically significant medical (including but not limited to CNS,&#xD;
             cardiovascular, hepatic, pulmonary, metabolic, or renal events), surgical, or&#xD;
             laboratory abnormality that would make study participation unsafe or make treatment&#xD;
             compliance difficult. Clinical significance to be determined by the Investigator.&#xD;
&#xD;
          4. Receipt of any investigational (ie, unapproved) medication or participation in any&#xD;
             clinical trial since completing the CTH 301 study.&#xD;
&#xD;
          5. Development of canker or mouth sores since completing the CTH 301 study. For other&#xD;
             clinically significant oral pathology, the Investigator should follow-up with an&#xD;
             appropriate specialist on any finding, if indicated, before enrolling such a patient&#xD;
             into the study. Clinical significance to be determined by the Investigator.&#xD;
&#xD;
          6. Current suicidal ideation as evidenced by answering &quot;yes&quot; to Question 4 or 5 on the&#xD;
             suicidal ideation portion of the C-SSRS at the Screening Visit Phase 2 (SVP2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CNS Medical Director</last_name>
    <phone>1-866-503-6351</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Muhammed Ali Parkinson and Movement Disorder Center/Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Movement Disorders Center of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Parkinson's and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health Gottschalk Medical Plaza</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center at USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hui</last_name>
      <phone>323-442-5710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research center of southern california</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Parkinsons Disease and Movement Disorders Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Treatment Center of Southwest Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience Associates Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>USF Parkinson's Disease and Movement Disorder Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Emory University Department of Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GRU Movement Disorders</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>NorthShore Neurological Institute B043D</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital - Neurodegenerative Clinic - Movement Disorders Center</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Dept. of Neurology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center-Department of Neurology</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Michigan State University - Dept. of Neurology</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Neurology</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Park Nicolet Institute - Stuthers Parkinson's Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center, Department of Neurology</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>David L. Kreitzman, MD, PC</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bendheim Parkinson's and Movement Disorder Center (Mount Sinai Medical Center)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Neurological Institute, Movement Disorders</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke University - Movement Disorders Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, P.A.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UT Gardner-McMaster Parkinson's Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Jefferson University Hospital Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia Adult Neurology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>322903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sentara Neuroscience Institute</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Evergreen Health</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck Neurology Department</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Poewe</last_name>
      <phone>00 43512504 81553</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital Department of Neurology</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Pirker, MD, PhD</last_name>
      <phone>43 1 49150 2001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UHN Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, CIC 1436, CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Rascol</last_name>
      <phone>0033 5 61 77 22 71</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Josef-Hospital, Klinikum der Ruhr-Universitaet-Bochum, Neurologische Klinik</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siegfried Muhlack</last_name>
      <phone>0049 234 509 6416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Neurologisches Studienzentrum im RKU</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Rainer Kassubek</last_name>
      <phone>0049 731 177 1206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria G Ceravolo</last_name>
      <phone>39 071 888989</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Ricerche San Raffaele</name>
      <address>
        <city>Cassino</city>
        <zip>03043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Francesca De Pandis</last_name>
      <phone>0039 336 823 486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aging Research Center, Ce.S.I. University Foundation, Chieti-Pescara Behavioural Neurology &amp; Movement Disorders Unit</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Onofrj</last_name>
      <phone>0039 0871 358525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana - Clinical Trial Center</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Stocchi</last_name>
      <phone>0032 0652 252311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Marti</last_name>
      <phone>00 34 932272143</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya</name>
      <address>
        <city>Sant Cugat del Vallés</city>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Balaguer Martinez</last_name>
      <phone>0034 9356 56000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings College, The Maurice Wohl Neuroscience Institute</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester University</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <state>Northumberland</state>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forth Valley Royal Hospital</name>
      <address>
        <city>Larbert</city>
        <state>Stirlingshire</state>
        <zip>FK54WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust NHS</name>
      <address>
        <city>London</city>
        <zip>W68RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Plymouth University</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

